Benitec Biopharma
BNTC
4 hedge funds and large institutions have $690K invested in Benitec Biopharma in 2019 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 2 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 1
0% less ownership
Funds ownership: 0% → 0% (-0%)
20% less funds holding
Funds holding: 5 → 4 (-1)
34% less capital invested
Capital invested by funds: $1.05M → $690K (-$359K)
50% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 2
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$46.2K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$2.71K |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$2.11K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$108K |
| 2 |
Renaissance Technologies
New York
|
-$10K |
| 3 |
VF
Virtu Financial
New York
|
-$8K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SM
1
Sabby Management
Miami Beach,
Florida
| $603K | -$108K | -716 | -13% |
|
|
2
Morgan Stanley
New York
| $80K | +$46.2K | +307 | +99% |
|
|
3
UBS Group
Zurich,
Switzerland
| $6K | +$2.71K | +18 | +75% |
|
|
4
Deutsche Bank
Frankfurt Am Main Ge,
Germany
| $1K | +$2.11K | +14 | New |
|
|
5
Renaissance Technologies
New York
| – | -$10K | -54 | Closed |
|
|
VF
6
Virtu Financial
New York
| – | -$8K | -44 | Closed |
|
BNTC Hedge Fund Activity: Q4 2019 in Review
4 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Benitec Biopharma (BNTC) for Q4 2019, worth a combined $690K — down 34% from $1.05M a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of BNTC and 1 opened new positions — a net loss of 1 holder — while 1 trimmed existing stakes and 2 added.
The largest buyer was Morgan Stanley, adding an estimated $46.2K. The largest seller was Sabby Management, cutting an estimated $108K.
- 4 institutional investors held Benitec Biopharma (BNTC) as of Q4 2019, down from 5 in Q3 2019.
- Funds reported $690K of Benitec Biopharma stock for Q4 2019, down 34% quarter-over-quarter.
- 1 fund opened new Benitec Biopharma positions in Q4 2019 and 2 closed out, a net change of -1 holder.
- The largest Benitec Biopharma buyer in Q4 2019 was Morgan Stanley, an estimated $46.2K added.
- The largest Benitec Biopharma seller in Q4 2019 was Sabby Management, an estimated $108K sold.
Based on aggregated 13F filings for Q4 2019.